MetLife vs Reinsurance Group of America
MET and RGA side by side, both in life insurance. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MET and RGA compare
MetLife is the larger company, worth 3.7 times as much as Reinsurance Group of America ($64.5B against $17.5B).
On earnings, Reinsurance Group of America is cheaper: it trades at 11.8× trailing earnings, against 13.2× for MetLife.
Reinsurance Group of America grew revenue faster over the last twelve months (19.4% versus 14.8% for MetLife).
MetLife keeps more of each dollar of sales as profit, with a net margin of 6.2% compared with 5.8% at Reinsurance Group of America.
Both pay dividends: MetLife yields 1.7% and Reinsurance Group of America 1.1%.
Reinsurance Group of America scores higher on the StockData Score (11 against 10 for MetLife), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MET | RGA |
|---|---|---|
| Size and price | ||
| Market cap | $64.5B | $17.5B |
| Share price | $101.50 | $268.29 |
| Change, 1 year | 29.1% | 42.2% |
| Change, 5 years | 68.9% | 176% |
| Beta (5Y) | 0.68 | 0.45 |
| Employees | 46K | 4,300 |
| StockData Score | ||
| Total score | 10 | 11 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 2 (better) | 0 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 13.2× | 11.8× (better) |
| P/S | 0.8× | 0.7× (better) |
| P/B | 2.9× | 1.3× (better) |
| EV/EBITDA | 5.6× | – |
| PEG | – | 0.36 |
| Fair value | $74.02 | $273.09 |
| Margin of safety | −37.1% | 1.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.8% | 19.4% (better) |
| Revenue growth, 5Y average | 2.6% | 10.2% (better) |
| Net income growth (TTM) | 33.5% | 95.8% (better) |
| EPS growth (TTM) | 44.4% | 97.7% (better) |
| EPS growth, 5Y average | −3.7% | 22.9% (better) |
| Profitability | ||
| Operating margin | 8.2% | – |
| Net margin | 6.2% (better) | 5.8% |
| Return on equity | 20.0% (better) | 11.7% |
| Financial health | ||
| Debt / equity | 0.01 | – |
| Net debt / EBITDA | −4.06 | – |
| Altman Z-score | 0.28 | 0.31 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% (better) | 1.1% |
| Payout ratio | 29.4% | 16.2% |
| Years of dividend growth | 13 (better) | 4 |
| Dividend growth, 5Y average | 4.3% | 4.9% (better) |
| Buyback yield | 4.0% (better) | 1.6% |
| Shareholder yield | 5.7% (better) | 2.7% |
| Ownership | ||
| Held by institutions | 76.5% | 99.4% |
| Held by insiders | 16.1% | 0.30% |
| Insider net buying, 12 months | −$21.0M | −$4.7M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.0% | – |
Go deeper
- MET stock overview
- MET income statement
- MET valuation and score
- RGA stock overview
- RGA income statement
- RGA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.